Victor Aboyans, MD, PhD, FESC, FAHA
Pr. Victor Aboyans is the Head of the Department of Cardiology at the Dupuytren University Hospital in Limoges, France, since 2012.
After his years of medical school at the University of Nice, and residency in the Limoges university, he has been graduated (MD) in 1996. He worked 15 years as an assistant and then as a senior physician in the Department of Cardiovascular Surgery where he developed his skills of peri-operative management after cardiac surgery as well as the medical management and imaging of patients with peripheral arterial diseases. In parallel he obtained a PhD in Public Health after a thesis on PAD epidemiology at Toulouse University, and prolonged his works by a one-year research stay at the University of California, San Diego. He has been nominated as Professor in Cardiology in 2011.
His research is mostly based on epidemiology of cardiovascular diseases and he is currently a senior member of an INSERM-labelled research team oriented in the epidemiology in tropical countries. His clinical research is mostly oriented to the management of vascular diseases and cardiac risk stratification through cardiac and vascular ultrasound markers. He authored more than 200 pubmed-referenced papers.
He is highly invested in the activities of the European Society of Cardiology. He has been the co-chair of the 2014 ESC guidelines on the management of aortic diseases, and he recently chaired the 2017 ESC guidelines on management of peripheral arterial diseases. He is the upcoming chair of the ESC working group of Aorta & Peripheral Vascular Diseases, starting in September 2018.
RA Ajjan (MD, FRCP, MMed.Sci, PhD) is an Associate Professor/Consultant in Diabetes and Endocrinology at Leeds University and Leeds Teaching Hospitals Trust, UK. He obtained his PhD from the University of Sheffield and completed his clinical training in Diabetes and Endocrinology at Leeds Teaching Hospitals Trust. He runs a programme of basic, translational and clinical research, aiming to improve clinical outcome in patients with diabetes. His research interests include analysing the effects of hyperglycaemia and hypoglycaemia on the risk of developing atherothrombotic complications in diabetes, which remain the main cause of mortality in this population. In particular, his research is focussed on understanding the role of high and low glucose levels on predisposition to a prothrombotic environment in diabetes.
Moreover, he is exploring diabetes-specific pathways for hypofibrinolysis, a key abnormality in this condition, in order to uncover new therapeutic targets for the reduction of thrombosis risk. He has a keen interest in implementing new glucose monitoring strategies to optimise glycaemic control by reducing glucose levels while minimising the risk of hypoglycaemia and limiting glucose variability. His clinical practice concentrates on young adults with diabetes as well as older diabetes patients with macrovascular complications.
He has more than 130 publications that include original articles, reviews and book chapters. He is the clinical research lead for Diabetes and Endocrinology in Leeds, co-lead of the “Thrombosis Group” at Leeds University and regional research network lead for endocrine and metabolic disorders.
Felicita Andreotti is a tenured Professor of cardiology at the Catholic University in Rome. She received an MD and two specialties in Italy and a PhD in the Netherlands. In 1990 she was Principal Investigator of a British Heart Foundation project, in 1993 Lecturer in Cardiology at the London University/Hammersmith Hospital, in 2006 Coordinator of a Ministry-funded project on acute myocardial infarction, and in 2008 Chair of the European Society of Cardiology (ESC) Working Group on Thrombosis. She has experience setting up a biochemical research lab. She is currently active in clinical studies and patient care.
Charis is a full Professor of Cardiovascular Medicine at the University of Oxford. He studied Medicine in Athens University Medical School and graduated with hons (top 3%) in 2000. He was awarded his PhD title with hons on the genetics of premature myocardial infarction, and during his PhD studies he won multiple Young Investigator award (YIA) competitions, including those of the European Society of Cardiology (ESC) twice, the International Society of Heart Research, British Atherosclerosis society and others. In 2011 he became a Principal Investigator in the University of Oxford and he is currently a Professor of Cardiovascular Medicine. He is funded by the British Heart Foundation, the National Institute of Health Research (NIHR), the European Commission, the NovoNordisk foundation and other funding bodies. His research is focused on the study of the cross-talk between adipose tissue and the cardiovascular system in humans, with specific interest in molecular imaging of vascular inflammation. He directs the Oxford Heart Vessels and Fat programme, with total funding over £5m, and recently he has developed a novel CT-based technology that detects tissue inflammation non-invasively. Since 2015, he directs the Oxford Academic cardiovascular CT programme. He has published more than 220 full length papers on this topic, and he has an h index of 58 with >9.6k citations (March 2018). He practices as a Consultant Cardiologist at Oxford University Hospitals NHS Trust, and he also runs the Trust’s hypertension service. In 2011 he was honoured with the prestigious “K Samaras” award of the Hellenic Heart Foundation and the University of Athens, and in 2015 he gave the “John French” lecture of the British Atherosclerosis Society. In 2016, he received the outstanding achievement award of the ESC, one of the highest honours awarded by the Society. He routinely gives invited lectures in the most prestigious international scientific meetings like the scientific sessions of the American Heart Association, the ESC, and others. He is also deputy editor of Cardiovascular Research, editor of British Journal of Pharmacology and associate editor of Hellenic Journal of Cardiology. He is board member of the British Atherosclerosis Society and one of the founders of the Scientists of Tomorrow of the ESC. He is also founder, shareholder and Chief Scientific Officer of Caristo Diagnostics, a university of Oxford spinout company.
2017: Expert Interventional Cardiology Licence
2017: Echocardiograpy licence, Heart Center Balatonfüred, Balatonfüred, Hungary
2013: Consultant Cardiologist, Heart Center Balatonfüred, Balatonfüred, Hungary
2010: Interventional Cardiology Licence
2009: PhD degree
2005: Medical Degree, University of Pécs, Hungary
• CURRENT POSITION(S)
2015- : Chief consultant cardiologist, Heart Center Balatonfüred
2014- : Assistant professor, Heart and Vascular Center, Semmelweis University, Budapest, Hungary
• PREVIOUS POSITIONS
2010-2013: Interventional cardiology fellow, cardiologist resident, Heart Institute, University of Pécs, Hungary
• FELLOWSHIPS AND AWARDS
2006: Fellowship: Hospital Cochin, Paris, France (C. Spaulding)
2005: Fellowship: Krakow, Jagiellonin University, Poland (D. Dudek)
2011: „Young Investigator Award“ CRT 2011 Conference Washington DC, USA 2014: Parmley Price: Best manuscript in JACC by an early-carrier first author
• SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS
2015-2017: 2 PhD students in training
• TEACHING ACTIVITIES
2014- : Teaching position – Antithrombotic therapy: Heart and Vascular Center, Semmelweis University, Budapest, Hungar
• ORGANISATION OF SCIENTIFIC MEETINGS
2017: Secretary, Annual Congress of the Working Group on Interventional cardiology of
the Hungarian Society of Cardiology
• INSTITUTIONAL RESPONSIBILITIES (if applicable)
2015- : Chairman, Institutional Research and Scientific Board, Heart Center Balatonfüred
• COMMISSIONS OF TRUST (if applicable)
2014: Editorial Board Member, Advances in Interventional Cardiology
• MEMBERSHIPS OF SCIENTIFIC SOCIETIES
2016: Secretary of the Working Group on Interventional Cardiology of the Hungarian Society of Cardiology
2015- : Member of the Working Group on Thrombosis of the European Society of Cardiology 2014- : Executive Board member of the Working Group on Interventional Cardiology of the
Hungarian Society of Cardiology
2010- : Secretary of the Hungarian Working Group of Thrombosis of the Hungarian Society of Cardiology
• MAJOR COLLABORATIONS
2014. Steering committee member, national study coordinator, site PI:
- TROPICAL ACS trial (Phase III multinational randomized IIT)
Lancet. 2017 Aug 25. pii: S0140-6736(17)32155-4.
2016. National site coordinator, site PI:
- COOL AMI PILOT trial (Phase III multinational randomized device trial)
EuroIntervention. 2017 Aug 4;13(5):e531-e539.
2017. National site coordinator, site PI:
- COOL AMI PIVOTAL trial (Phase III multinational randomized device trial)
• SCIENTIFIC GRANTS
2015-2017: János Bolyai Scholarship, Title: Individualized antiplatelet therapy in patients after PCI
Harald Arnesen, born October 21. 1938 in Oslo, Norway
High School graduation: Oslo 1957
Medical doctor at University of Oslo 1963
Ph D at University of Oslo 1974 on the Thesis:
"Studies on Fibrinogen/Fibrin Degradation Products"
Specialist in Internal Medicine, Norway 1978
Specialist in Cardiology, Norway 1979
Clinical and Research training at Depts. of Internal Medicine, Haematology and Cardiology at Ullevål University Hospital 1966-81
Medical Head at Red Cross Clinic, Oslo 1981-89
Director (daily leader) of Research Forum, Ullevål University Hospital 1990-92
Head of Competence Center for Clinical Research, Ullevål University Hospital 2000-2007
Head of Medical Out-patiernt Clinic, Ullevål University Hospital 1992-2009
Head of Center for Clinical Heart Research, Ullevål University Hospital 1991-2012
Professor of Medicine, University of Oslo 1992
Member of Int Soc on Thrombosis and Haemostasis
Int Soc for Fibrinolysis and Thrombolysis
Norwegian Soc of Internal Medicine
Norwegian Soc of Haematology
Norwegian Soc of Cardiology
Fellow of European Soc of Cardiology (ESC) 1994
Member of Working group Thrombosis in ESC from 1998, the Nucleus from 2005-09, Vice-chair 2007-09.
Editor Thrombosis Research 1999-2005.
Scientific publications: 390 original articles in journals with peer review. H-index 50.
340 published congress abstracts.
Main topics: Haemostasis; Cardiology; Atherosclerosis; Clinical trials.
Research supervision: 45 doctoreal fellows, of which 41 have finished their Ph D theses.
Member of the scientific judgement committee for 35 doctoreal theses at the universities in Oslo, Tromsø, Bergen, Uppsala, Stockholm, Aarhus and Aalborg.
Member of scientific judgement committee for 10 professorship applications.
Receiver of Norwegian Health Association prize (“Hjerteprisen”) 2005.
“Doctor medicinae honoris causa” (“Æresdoktor”) at Aalborg University 2017.
Prof. Lina Badimon is the Director of the Cardiovascuolar Program ICCC - Institut de Recerca, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research. Her research activities focus on cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease. She has published over 495 articles in highly qualified scientific journals with her work highly quoted in the scientific literature (Citations: 29.495; h‐index 70). She has written more of 250 reviews and book chaptersShe is Member of Editorial Boards of various international scientific journals. Previous appointments include: Fellow in Cardiovascular Diseases at The Mayo Clinic, Rochester, MN, USA (1981‐1983); Director of the Cardiology Basic Research Laboratory of the Division of Cardiology at the Mount Sinai Medical Center, New York, NY (1983‐1991); Assistant Professor of Medicine (1983‐1987) and Associate Professor of Medicine (1988‐1991) at the Mount Sinai School of Medicine, NY; Lecturer in Medicine at Harvard Medical School, Boston (1991‐1994); Consultant at the Cardiac Unit, at the Massachusetts General Hospital, Boston (1991‐1994) Positions of Trust: Vice-President for Scientific Affairs of European Society of Cardiology (2016-2018), Vice‐President of the Spanish Society of Cardiology (2013‐2015); Chairman of the Council on Basic Cardiovascular Science (2014‐2016) and Chairman of the Working Group on Microcirculation (2012‐2014) of the ESC; Past‐President of the European Society for Clinical Investigation (2000‐2002) and Past‐President of the Spanish Society of Atherosclerosis (1996‐2000). Honorary Appointments: Fellow of the Cardiovascular Science Council and Fellow of the Atherosclerosis, Thrombosis and Vascular Biology Council of the American Heart Association; Fellow of the European Society of Cardiology; Distinguished Fellow of the International Atherosclerosis Society, Honorary Member of Spanish Society of Hypertension, of the Romanian Society of Hypertension, of Spanish Society of Arteriosclerosis. She has received the “Narcís Monturiol” (1993) and “Creu de Sant Jordi” (2004) Medals from Generalitat de Catalunya; the “Rey Jaime I” Award – Medical Research (2014) from Generalitat Valenciana and named Doctor Honoris Causa by the Carol Davila University of Medicine and Pharmacy, Romania (2015).
Marie-Luce Bochaton-Piallat completed her PhD in Biochemistry at the Faculty of Medicine of the University of Geneva in 1993. During her post-doctoral studies she was scientific coordinator at the Bioimaging Core Facility at the Faculty of Medicine until 2002 when she became an independent research group leader. She teaches cardiovascular pathophysiology at the Faculty of Medicine. She is a fellow of the European Society of Cardiology and elected member of the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. She also serves as member of the scientific committee of the Swiss CardioVascular Biology Working Group and section editor of The European Society of Cardiology Textbook of Vascular Biology. Recently she co-edited a spotlight issue on Novel concepts for the role of smooth muscle cells in vascular disease in CardioVascular Research.
She has a longstanding experience in the implication of smooth muscle cell heterogeneity in atherosclerosis and restenosis. She is working with the porcine coronary artery smooth muscle cells. Thanks to this experimental model, she identified the S100A4, a calcium-binding protein, as a marker of intimal smooth muscle cells, in both pig and human. She is currently investigating the role of S100A4 in the phenotypic modulation of intimal smooth muscle cells in vitro and in vivo. Since 2002 she receives continuous support from the Swiss National Science Foundation for her research. Her h-index is 32.
1974 – 1980 Medical School in Cologne, Germany
1977 – 1980 M. D., Ph. D. program, thesis work in biochemistry
31 Oct 1980 German Licence as physician (Regierungspraesidium of Cologne/Germany) and ECFMG Exam
18 Mar 1981 Dissertation (University of Cologne)
1981 – 1982 Doctor in the German draft army
1982 – 1983 Research fellow at the Institute of Physiological Chemistry at Cologne
1984 – 1986 Research fellow at Massachusetts General Hospital and Harvard Medical School, Boston, USA
1986 – 1992 Assistant Professor at the Department of Cardiology at the University of Heidelberg, Germany
1992 – 1998 Associate Professor in Heidelberg, Germany
1998 – 1999 Professor of Medicine in Heidelberg, Germany
01.04.1999 – Chairman of the Department of present Cardiology, Angiology at the University of Freiburg, Germany
2010 – 2016 European Editor of Circulation
2011 – 2013 Chair of the Program Committee and Member of the Board, German Cardiac Society
2011 – 2015 President Society of Thrombosis und Haemostasis (GTH), Switzerland, Austria, Germany
2013 – 2015 Chairman of the Assembly of International Governors (AIG) of the American College of Cardiology
2015 Honorary Doctor Maikop State Technological University
Christoph Bode is Professor of Internal Medicine and Chairman of the Department of Cardiology, Angiology at the University of Freiburg, Germany. Professor Bode is an interventional cardiologist with a special interest in antithrombotic therapy in cardiovascular diseases. He has devoted much of his research to basic science and holds several patents in molecular targeting for diagnostic, therapeutic or imaging purposes. He has been awarded a number of special honors and his advice is sought by funding and government agencies.
Héctor Bueno leads the Multidisciplinary Translational Cardiovascular Research (MTCR) Groups at the Spanish National Cardiovascular Research Center (CNIC), and at Hospital Universitario 12 de Octubre, in Madrid, where he also serves as Scientific Director of the Cardiovascular Research Area in the imas12 Research Institute. His clinical work at the Cardiology Department is focused on the CCU. Dr. Bueno is Associate Professor of Medicine in Universidad Complutense de Madrid and has an active participation in the European Society of Cardiology (ESC) where he serves as Board Councillor and in several committees. He is the immediate Past-President of the Acute Cardiovascular Care Association (ACCA).
Héctor Bueno obtained his MD at Universidad de Navarra, Spain in 1988, completed his training in Cardiology at Hospital General Universitario Gregorio Marañón, in Madrid, and obtained his PhD with the extraordinary award for the best thesis of year 1996 by Universidad Complutense de Madrid. He also obtained a degree on Design and Statistics in Health Sciences by Universitat Autónoma de Barcelona, and a degree in Integrated Health Care Systems Direction at ESADE Bussiness School, Madrid. During year 2008, he served as Visiting Professor at Yale Medical School (New Haven, USA) where he worked on a Medicare Program for the development and analysis of performance measures for cardiac diseases (MI, HF). Dr. Bueno worked as Head of Clinical Cardiology in the Department of Cardiology, Hospital General Universitario Gregorio Marañón in Madrid until 2015. He has served in the past as President of the Working Group on Ischemic Heart Disease of the Spanish Society of Cardiology, and member of the Boards of the Council of Quality of Care & Outcomes Research of the American Heart Association (AHA) and the Society of Geriatric Cardiology in USA. He has been awarded as Fellow of the AHA and ESC (FAHA, FESC).
Héctor Bueno has a long career in individual and cooperative clinical research, having been recipient of several national and international competitive grants. He has authored or co-authored more than 250 publications in journals, such as NEJM, Lancet, JAMA, Circulation, JACC, Eur Heart J, and serves on the editorial boards of a number of international cardiology journals. long experience in international expert panels and advisory boards for scientific, strategic and commercial planning and organization. His scientific interests include a broad range of topics, including acute cardiovascular care, ACS, heart failure, geriatric cardiology, brain-heart connections, atherogenesis, antithrombotic therapies.
Alfonso Bueno - Orovio
Alfonso Bueno - Orovio
Dr Alfonso Bueno-Orovio obtained his PhD from the University of Castilla-La Mancha (Spain, 2007) in modelling and simulation of human ventricular electrophysiology, followed by industrial experience and a post-doctoral position at the Technical University of Madrid. He then joined the Computational Cardiovascular Science group at the University of Oxford in 2010, in the development of synergistic data-driven approaches for cardiovascular research. In 2017 he became one of the few computational Intermediate Basic Science Research Fellows of the British Heart Foundation. His work covers the many facets of structural-function interplay and population variability in the human heart, where modelling and simulation are used to augment experimental and clinical findings to investigate cardiac arrhythmias and mechanisms of drug action under different pathological conditions.
Enrico G. Caiani (MS 1996, PhD 2000) is Associate professor at the Electronics, Information and Bioengineering Dpt., Politecnico di Milano, Italy, where he teaches the classes of “E-health: applications” and “Biomedical Image Processing Laboratory”. Author of 5 book chapters and 90 papers in ISI journals (IF 190, H-index=18, total citations>1400), in the last years he participated in the program committee of several eHealth conferences, also as invited speaker on eHealth related talks.
He was involved in several Italian, EU, ESA, and other international research projects. Actually, he is co-investigator of the project “Linking excellence in biomedical knowledge and computational intelligence research for personalized management of Cardio Vascular Disease within Personalized Health Care”, European Union H2020-TWINN-2015, as well as Principal Investigator of several projects in the field of space physiology to study cardiac modifications induced by microgravity, also using new technological solutions.
Currently, he is serving as Chairperson (16-18) for the e-Cardiology Working Group of the European Society of Cardiology (ESC), he is part of the ESC Advocacy group, and represents the ESC at the European Commission eHealth Stakeholder group.
His main research interests include e-health solutions and m-health applications in the field of cardiology, cardiac image processing and space physiology.
Dr. Ángel R. Cequier Fillat
- Director Heart Disease Institute, Bellvitge University Hospital
- Head. Cardiovascular Group Research. IDIBELL (Bellvitge Research Institute)
- President-Elect Spanish Society of Cardiology (2017- )
- Residence in Cardiology (Bellvitge University Hospital, 1980 - 1986)
- PhD (University of Barcelona - 1994)
- MCCEFG: Medical Council of Canada. Ottawa. Canada. (1987)
- Clinical and Research Fellowship in Interventional Cardiology: Montreal Heart Institute. Universidad de Montreal. Canada. (1986-1988)
- Professor of Cardiology. University of Barcelona.
- Spanish Society of Cardiology, Fellow European Society of Cardiology.
- Editorial boards: “Clínica e Investigación en Arteriosclerosis”, “Revista Española de Cardiología”, “Revista Latinoamericana de hemodinámica Angiografía y Terapéutica por Cateterismo” and “Práctica Cardiología”.
- Publications: Three hundred articles published in National Journals and in International Journals (New England Journal of Medicine, Lancet, Circulation, European Heart Journal, Journal American College of Cardiology, etc Twenty books or book chapters, 4 directed doctoral theses, 400 national or international lectures and presentations.
Jean-Philippe COLLET MD, PhD
Administrative and Academic Appointments
Director of the Interventional Catheterization Laboratory
- Interventional Cardiologist at the Institut de Cardiologie
- Hôpital de la Pitié-Salpêtrière, Sorbonne Université
Director of the Cardiovascular Training Program at the Université Pierre et Marie Curie
- Professor of Cardiology at Sorbonne Université (UPMC_Paris 6)
- Co-director of the INSERM 1166, UPMC, Paris 75013
Director of the Research Unit on Thrombosis, Atherothrombosis and Applied Pharmacology
- Five full time persons
- Main research objectives:
- New models for experimental thrombosis
- Demonstration of the prognostic role of biomarkers
- Comparative evaluation of antithrombotic therapies
- Reassessment of antithrombotic drug regimens (PK and PD models for drug evaluation)
- Phase 1 study for oral antithrombotic treatment
- Core laboratory for angiography and biology
- Randomized trials (www.action-coeur.org).
Certifications and Scientific Societies
− Specialist in cardiology (MD), Université Paris XII
− PhD in Thrombosis, University of Rouen, France
− Member of the French Society of Cardiology
− Member of the European Society of Cardiology (FESC)
− Nucleus Member of the Working Group 18 (Thrombosis)
− Member of EAPCI
− Member of the Clinical Practice Guidelines Committee
Dr Jean-Philippe Collet is a Professor of Cardiology at Pitié-Salpêtrière University Hospital in Paris where he leads the interventional catheterization unit (PCI and TAVI). His main expertise is in the field of thrombosis, the effect of antithrombotic agents and the development of new devices for structural heart intervention. He has been a pioneer in the field of thrombus structural properties but also in the pharmacogenetic of clopidogrel treatment and platelet function testing. He is a member and a founder of the Academic Research Organisation A.C.T.I.O.N (Alliés in Cardiovascular Trials, Initiatives and Organized Networks) (www.action-coeur.org). He has led clinical trials as a principal investigator (AMERIC A, DOSAPI, ARCTIC and ATLANTIS). He has several commitments in the ESC. He is a Fellow of the European Society of Cardiology, a member of the nucleus of the WG Thrombosis and a member of the Clinical Practice Guidelines Committee. He is serving as an expert in several ESC guidelines. He has served as the Chair of the EAPCI scientific program for two years (2014-2016).
− Articles: 420
− Book chapters: 45
− Abstracts: 200
1. Collet JP, Silvain J, Barthélémy O, Rangé G, Cayla G, Van Belle E, Cuisset T, Elhadad S, Schiele F, Lhoest N, Ohlmann P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Montalescot G; for the ARCTIC investigators. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet 2014 6736(14) : 60612-7.
2. Montalescot G, Rangé G, Silvain J, Bonnet JL, Boueri Z, Barthélémy O, Cayla G, Belle L, Van Belle E, Cuisset T, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Beygui F, Vicaut E, Collet JP; ARCTIC Investigators. High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC study. Circulation. 2014 May 27;129(21):2136-43.
3. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, M D EV, Montalescot G; the ARCTIC Investigators. Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting. N Engl J Med. 2012; 367(22):2100-9
4. Cayla G, Hulot J-S, O’Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou J-B, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet J-P. Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. JAMA. 2011; 306:1765–1774.
5. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, Payot L, Brugier D, Cayla G, Beygui F, Bensimon G, Funck-Brentano C, Montalescot G. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009 ;373(9660):309-17.
Maria G. Crespo-Leiro, MD, PhD, FESC, FHFA
Coordinator of the Advanced & Specialized Heart Failure (HF) and Heart Transplant (HT) Unit at the Complexo Hospitalario Universitario A Coruña (CHUAC), Spain and Associate Professor of Medicine.
She obtained MD at the University of Santiago de Compostela, Specialization in Cardiology at Clinica Puerta de Hierro in Madrid and PhD from Universidad Autónoma de Madrid.
President of the Spanish Working Group on Heart Failure and Heart Transplantation, (2003-2007)
Member of the Board of Directores of the International Society for Heart and Lung Transplantation (ISHLT) (2010-1013).
Member of the Board of the Heart Failure Association (HFA) of the ESC (2012-2018). Secretary of the HFA Executive Committee (2016-2018)
Chair of the HFA Advanced Heart Failure Committee (2017-ongoing)
Her main fields of research interest are heart failure and heart transplantation.
Dirk J. Duncker obtained his PhD and MD degrees, respectively, in 1988 and 1989 at the Erasmus University Rotterdam. He worked as a post-doctorate research fellow at the University of Minnesota from 1991-1994, after which he returned to the Department of Cardiology (Thoraxcenter) of the Erasmus MC, University Medical Center Rotterdam. In 1995 he received a 5 year Research Fellowship Stipend from the Royal Netherlands Academy of Arts & Sciences, and in 2000 he became Established Investigator of the Netherlands Heart Foundation. He was appointed Professor of Experimental Cardiology in 2003. His research interests include the regulation of coronary blood flow and coronary microvascular tone in health as well as in a variety of cardiovascular disorders, including metabolic disorders, ischemic heart disease, cardiac hypertrophy and heart failure.
Jesus Egido MD,PhD . Emeritus Professor . Autonoma University . Consultant Chief, Division of Nephrology and Hypertension .Director, Renal, Vascular and Diabetes.Research Laboratory, University Hospital Fundacion Jimenez Diaz in Madrid , and extraordinary Professor of Medicine at Austral University in Chile . The major interest of his lab is the study of cellular and molecular mechanisms involved in the genesis and progression of cardiovascular and renal diseases , as well as the search of novel therapies . Author of more than 600 papers in international journals . Member of several Scientfic Societies and editorial boards as well as recipient of various research awards .
Professor Javier Escaned MD PhD FESC is Head of the Interventional Cardiology Section and Associate Professor at the Cardiology Department, Hospital Clinico San Carlos (Madrid, Spain), and Complutense University of Madrid. He has over 25 years of clinical experience in interventional cardiology, and trained as a cardiologist the United Kingdom (Queen Elizabeth University Hospital, Birmingham and Walsgrave Hospital, Coventry) before moving to the Thoraxcenter / Rotterdam (The Netherlands), where he obtained his PhD degree in 1994. He is author of more than 300 scientific articles, books and book chapters on interventional cardiology, imaging and physiology (H-index 50). Recent multicentre trials in which he has a principal investigator role include ADVISE II, SYNTAX II, and DEFINE-FLAIR. He is editor of two large textbooks, “Coronary Stenosis. Imaging, Structure and Physiology” (PCR Books, second edition May 2015; Patrick W Serruys co-editor) and “Physiological Assessment of Coronary Stenoses and the Microcirculation” (Springer, 2017; Justin Davies, co-editor). Recent positions in scientific societies include: board member of European Association of Percutaneous Cardiovascular Interventions (EAPCI), board member of the EuroCTO Club, nucleus member of the ESC Working Group on Pathophysiology and Microcirculation, and co-director of EuroPCR. Some of his additional interests are philosophy, education and music.
Professor Christine Espinola-Klein
Since 2003 Senior physician section of angiology
Since 2009 “Professorship for angiology”, University Medical Centre at the Johannes Gutenberg-University, Mainz
Approval as medical specialist for:
- internal medicine (2002)
- angiology (2003)
- cardiology (2004)
- haemostaseology (2015)
2003 Habilitation, University Medical Centre at the Johannes Gutenberg-University, Mainz
Title of the work: “Pathophysiological and prognostic aspects of atherosclerosis in different vascular territories”
Fields of research: poly-vascular atherosclerosis, peripheral arterial disease, inflammation in atherosclerosis, treatment of peripheral arterial disease, secondary prevention of atherosclerosis
Clinical expertise: epidemiology, diagnosis and therapy of peripheral atherosclerosis, Doppler- and duplex sonographic examination of arterial and venous system, endovascular treatment of peripheral arterial disease, anticoagulation and antiplatelet therapy
Marcus Flather graduated from the Royal Free Hospital School of Medicine, (University of London) in 1982 and trained in general medicine and cardiology in London and Oxford. He is an international expert in cardiovascular clinical trials in acute coronary syndromes (heart attacks and related conditions) and heart failure. He has more than 220 peer reviewed publications and 25 years of experience in collaborating with academic and industry partners in drug and device development.
Sheila Francis is Professor of Cardiovascular Biology and Head of Infection, Immunity and Cardiovascular Disease at the University of Sheffield. She has had a long-standing interest in interleukin-1 and atherosclerosis including the first demonstration of IL-1 in human coronary arteries (ATVB 2006), genetic susceptibility to coronary artery disease determined by variants at the IL-1 locus (Circulation, 1999), endothelial lifespan influenced by interleukin-1 (Circ Res 2003), release of IL-1 from endothelium by neutrophil elastase (JBC 2015) and the use of numerous preclinical models of vascular disease. These fundamental studies were used to underpin the MRC ILA HEART study conducted in Sheffield (EHJ, 2015), the precursor to the CANTOS trial (NEJM, 2017).
Her publications can be found at orcid.org/0000-0001-6552-0339
Since March 2016: Head of interventional valve programme with main focus on TAVR and structural heart interventions
April 2015: Certfication interventional cardiology by the German Cardiac Society
August 2014: Fellowship of the European Society of Cardiology
April 2014: Election as nucleus member of the working group “cardiovascular hemostasis and antithrombotic therapies” of the German Cardiac Society
Since November 2015: Vice Head of department of cardiology, University Hospital Tübingen
May 2014 - October 2015: Head of chest-pain-unit / department of cardiology, University Hospital Tübingen
June 2013: Associate Professorship in Cardiology since
September 2011: Consultant Interventional Cardiology, University Hospital Tübingen
December 2010: Habilitation (Associate Professorship)
June 2011: Board certification cardiology
September 2009 to October 2010:
Senior Research Fellow Clinical Trials and Evaluation Unit/Royal Brompton Hospital, Imperial College London, UK
Full medical licence with specialist registration by the UK General Medical Council
August 2009: Board certification internal medicine
June 2005 to August 2009: Residency at the Department of Cardiology and Cardiovascular Medicine, University Hospital Tübingen, Germany (chairman Prof. Dr. M. Gawaz), research interests: platelet function analysis in cardiovascular risk patients, platelet pharmacogenetics interventional cardiology
2003 – 2005 Internship at the Department of Internal Medicine, Hospital
Schwalmstadt, Germany (chairman Prof. Dr. R. Zotz, MD), research interests: cardiovascular imaging, contrast and 3D-echocardiography
July 2004: Medical license
Thesis Supervisor: Prof. Dr. E. Weihe, MD, Department of
Anatomy and Cellular Biology, University Marburg, Germany
Title: Superantigen-induced effects on IL-2 receptor expression
and proliferation of CD4- and CD8-positive T cells in the rat
2001 Clinical clerkship at the Department of Cardiothoracic Surgery,
chairman Professor Cosgrove, MD, Cleveland Clinic, Ohio, USA
1998 – 1999 Medical school University Lund / Sweden
1996 – 2002 Medical school University Marburg, Germany
1995 – 1996 Military service
1986 – 1995 Grammar school
2006 Award of the German Heart Foundation for the work "Clinical
relevance of clopidogrel resistance"
August 2009: Atherothrombosis Grant of the European Society of Cardiology,
Research Fellowship at the Royal Brompton Hospital, London,
UK / Prof. M. Flather
December 2009: Award of the German Diabetes Foundation
platelet biology, pharmogenomics of antiplatelet and
antithrombotic therapies, platelet-mediated inflammation,
platelet and diabetes, epidemiology, translational medicine
clinical trials, structural heart interventions
head of the clinical research unit at the department of cardiology,
Principal Investigator of several multi-centric and investigatorinitiated
clinical trials in the area of interventional cardiology,
thrombosis and angiology
reviewer for numerous journals including BMJ, Journal
Thrombosis Haemostasis, American Journal Cardiology,
European Heart Journal, Thrombosis and Haemostasis, JAMA,
Diabetes Care, Archives Internal Medicine, J Am Coll
Bruna Gigante graduated in Medicine (1994) and obtained the degree as specialist in Cardiology (1998) at the Federico II University in Naples, Italy. She has then been working about 3 years in Klaus Lindpaintner´s genetic epidemiology lab at Harvard Medical School, Boston, MA, USA as research fellow and thereafter pursued a PhD degree in Experimental Medicine (2002-2006) at the Federico II University in Naples. After graduation, Bruna moved to and has been working first as post doc (2007-2010) then as assistant professor (2011-2015) at the Unit of Cardiovascular Epidemiology at the Institute of Environmental Medicine (IMM) at Karolinska Institutet (KI). From 2012 Bruna has started working again actively as a clinician at the Department of Cardiology at Danderyd´s Hospital (Stockholm) and from December 2015 holds a position as senior lecturer in cardiovascular medicine, a position that combines clinical and research work. From 2017 she has been appointed research group leader at IMM and project leader for the KI-Makerere University (Uganda) collaboration to establish a novel cardiovascular cohort to identify clinical and biological risk markers for cardiometabolic diseases in Uganda. She has authored/co-authored some 100 scientific publications in peer-reviewed international journals. At present Bruna leads a research group 2 PhD students and 1 pre PhD student. Overarching aim of her research group´s line of research is to discover and validate biomarkers that can be used as independent predictors of cardiovascular events and to identify novel target for treatment. She has received funding from internal and external sources both as main applicant and as co-applicant.
At present she is a member of the steering committee of the strategic research in epidemiology and of the cardiovascular research program at KI. She has been involved in several international collaborations both in large consortia and in multi-center studies that have resulted in publications in journals with medium/high impact factor. Bruna is involved in teaching as course leader and teacher in postdoctoral courses and courses for specialists in training. In addition, she has acted as supervisor of both graduate and undergraduate students.
Diana Gorog is Professor of Cardiovascular Medicine at University of Hertfordshire and Visiting Professor at the National Heart and Lung Institute, Imperial College, London, UK. She is a Consultant Cardiologist and Clinical Lead for Research at East and North Hertfordshire NHS Trust, UK. Prof. Gorog trained in medicine at St. Bartholomew’s Medical School, University of London, and undertook her cardiology training in central London teaching hospitals. She obtained a postgraduate MD from Imperial College and PhD from King’s College, London. In addition to being an interventional cardiologist, including undertaking PPCI on call, she is actively engaged in clinical research on thrombosis, in particular platelet function testing, endogenous fibrinolysis and thrombosis risk assessment.
Dr Grove has specialised in Internal Medicine:Cardiology and in Thrombosis & Haemostasis. He is a clinical cardiologst at Aarhus University Hospital in Denmark and has a PhD in platelet function testing and platelet turnover in coronary artery disease. He works in a thrombosis clinic and also with cardiac CT. Other areas of interest include antithrombotic therapy, acute cardiac care, diabetes mellitus, atrial fibrillation and oral anticoagulants, including warfarin, self-monitored anticoagulant therapy, DOACS, switching, and drug-drug interactions. He is an author/co-author of >140 publications, and his research include laboratory studies, clinical studies and registry-based pharmaco-epidemiology.
Sigrun Halvorsen (MD, PhD, FESC) is Professor at the University of Oslo and Head of the Department of Cardiology, Oslo University Hospital Ulleval. Professor Halvorsen is a clinical cardiologist with a special interest in acute coronary syndrome (ACS) and antithrombotic treatment. She defended her Thesis in the field of basic coagulation/fibrinolysis in 1995, was certified as a specialist in Internal Medicine in 1997 and as a Cardiologist in 2000. Since September 2013 she has held the position as Head of Cardiology at Oslo University Hospital Ulleval, one of the largest cardiology departments in Norway. She has published over 120 scientific papers with over 8000 citations in peer-reviewed journals and has been the supervisor for many PhD students. Halvorsen is a Fellow of the European Society of Cardiology (FESC) since 2008 and a member of several ESC working groups and associations. In 2012-2016 she served as a Nucleus Member of the ESC Working Group on Thrombosis, and at present she is Board member of the ESC Acute Cardiac Care Association. She has also participated in several of the Task Forces for ESC Clinical Practice Guidelines (e. g. STEMI-guidelines 2012 and 2017), and is a frequently invited speaker to national and international congresses.
Borja Ibáñez (Madrid, 1975), MD PhD is a Cardiologist with a main interest in acute myocardial infarction. He combines research activities as Director of the Clinical research Department of the National Center for Cardiovascular Research (CNIC) in Spain with clinical activities as interventional cardiologist at the University Hospital Fundación Jiménez Díaz.
After completing his training as full cardiologist in Spain, he was trained in cardiovascular research at Mount Sinai School of Medicine, new York USA. Borja has been dedicating his entire career to acute myocardial infarction and post-infarction heart failure, both at research and clinical levels. His research is highly translational with a clear clinical impact focused on performing clinical trials arising from preclinical data generated by his laboratory group. Borja is an expert on the role of the beta-adrenergic system modulation in cardiovascular diseases and in the use of imaging for myocardial tissue characterization. He has been the leader of the research program repurposing metoprolol use as a drug able to reduce long-term post-infarction heart failure and he is also active in the search of other targets that could be brought to the clinical arena in the future. He is/has been principal investigator of several multicenter clinical trials recruiting patients with STEMI.
He is the Chairman of the 2017 ESC STEMI Clinical Practice Guidelines.
He is PI of several national and international projects, including H2020-funded grants. He has published more than 120 scientific publications in high-impact journals in the cardiovascular field, most of them as main author (Science, New Engl J Med, Lancet, Nature Medicine, Circulation, J Am Coll Cardiol, Eur Heart J, Circ Res) as well as 15 book chapters, more than 50 invited conferences, more than 200 meeting contributions and over 10 scientific awards, highlighting “Principe de Girona Award in science” for his “contribution in the field of cardiology translational research”.
He serves as Associate Editor in the Journal of the American College of Cardiology (the leading journal of cardiovascular diseases area), and he is in the editorial board of Basic Research in Cardiology and Journal of Cardiovascular Translational Research journals.
David Jiménez is Associate Professor of Medicine at the University of Alcalá de Henares, Madrid, Spain, and Chief of the Venous Thromboembolism Programme at the Ramón y Cajal Hospital in Madrid. He serves as Chief of the Respiratory Department of Ramon y Cajal Hospital. He received his medical degree cum laude from the University of Alcalá de Henares.
Dr Jiménez’s interests include venous thromboembolism, pleural diseases and malignant mesothelioma, and clinical care, education and research for patients with pulmonary embolism (PE). He is past President of the Vascular Sections of both the Spanish Society of Respiratory Medicine (SEPAR) and the Madrid Society of Respiratory Medicine (NEUMOMADRID).
Dr Jimenez has participated as Principal Investigator of several randomized clinical trials on thromboembolic prophylaxis and treatment. His research activity focuses on risk stratification and treatment of patients with PE. He was the Chairman of the PROTECT (prognostic value of CT scan for the prognosis of hemodynamically stable patients with PE) and the AINEP (diclofenac for patients with submassive PE) studies, and was a member of the Steering Committee of the PEITHO trial, which assessed the eficacy and safety of thrombolytics in intermediate-risk patients with PE.
He is also a member of several journal editorial boards, and is a peer reviewer for New England Journal of Medicine, The Lancet, JAMA, the Journal of Thrombosis and Haemostasis, Thrombosis and Haemostasis, or Chest.
Dr. Jimenez is co-chairman of the 10th edition of the Antithrombotic and Thrombolytic Therapy ACCP guidelines, and has been invited speaker at several national and international congresses and in a number of major universities worldwide.
Juan Carlos Kaski
Juan Carlos Kaski
JC Kaski, DSc, MD (Hons), FRCP, FESC, FACC, FAHA, FRSM, is Professor of Cardiovascular Science at St George’s, University of London (SGUL), Honorary Consultant Cardiologist at St George’s Hospital, London, and immediate Past-Director of the Cardiovascular and Cell Sciences Research Institute at SGUL. Prof. Kaski is Doctor Honoris Causa of several universities worldwide, a Past-President of ISCP (International Society of Cardiovascular Pharmacotherapy) and Fellow of over 30 scientific societies worldwide. He is Editor-in-Chief, European Cardiology Review, Deputy Editor, International Journal of Cardiology, Associate Editor, Cardiovascular Drugs and Therapy and editorial board member of JACC, the European Heart Journal and over 20 other scientific journals.
Prof Kaski’s research areas include inflammatory and immunological mechanisms of atherosclerosis, microvascular and vasospastic angina and biomarkers of cardiovascular risk. Prof Kaski has published over 400 papers in peer-review journals, over 200 invited papers and more than 130 book chapters. He has also edited eight books on cardiovascular topics and is Editor-in-Chief of the ISCP Cardiovascular Pharmacotherapy book series.
Marise J. Kasteleyn (PhD) (F) is a postdoctoral researcher at the Department of Public Health and Primary Care. She holds a master of sciences in Epidemiology and in Neurosciences, and a bachelor in psychology. Her research focus is on eHealth, chronic diseases, quality of life and primary care. She is the secretary of the eHealth steering committee of the LUMC and participates in the eHealth programme of the Netherlands Federation of University Medical Centres. Furthermore, Marise is a member of the National eHealth Living Lab team.
Irene Marthe Lang is a senior staff member at the Department of Cardiology, and has been Interimistic Chair of the Department, at the Medical University of Vienna, Vienna, Austria since Oct 1, 2016. Irene Lang carried out her medical education and residency at the University of Vienna, before taking on a 5-year postdoctoral research fellowship at the University of California, CA, USA, which included a joint appointment with the Scripps Research Institute, La Jolla, CA. She has been Professor of Vascular Biology at the Medical University of Vienna since 2004, where she leads a clinical and experimental group in vascular medicine focussing on pulmonary vascular biology and right ventricular function. Irene Lang directs an outpatient unit for pulmonary vascular disease at the Medical University of Vienna .
Irene Lang is an active interventional and structural cardiologist, recently very active as balloon pulmonary angioplasty interventionist, and an active researcher. She was nominated by the World Medical Association as a ‘Caring Physician of the World’ in 2006, ‘Teacher of the Year’ at Medical University of Vienna in 2013, and is past president of the Austrian Society of Cardiology. In April 2016 she was awarded the Großes Ehrenzeichen der Republik Österreich and an honorary doctorate from the University of Cyril and Methodius in Skopje, Macedonia. Irene Lang is part of the International CTEPH Association (ICA) whose objectives are to increase awareness for CTEPH, foster worldwide collaboration between CTEPH centers, serve as platform for surgical centers and facilitate training of emerging CTEPH centers, as well as to advance research and education in CTEPH.
Dr. Lindholm received his MD at Uppsala University and after his PhD in Cardiology which involved risk prediction and antiplatelet therapy he has spent time at Stanford University as a visiting scholar. He has published several manuscripts on biomarkers in coronary heart disease and their combination into clincally useful risk scores.
Francisco Marín, MD, PhD
Head of Clinical Cardiology. University Hospital Virgen de la Arrixaca
Senior Lecturer in Cardiology at the University of Murcia
Principal investigator of the Research Institute IMIB-Arrixaca, and member of the Excutive Committee of the Institute.
Principal investigator of the CIBER-CV Group of Arrixaca
Author of more than 300 articles, more than 10 book chapters and director of 18 doctoral theses.
Member of the Scientific Initiatives Committee of the EHRA, author of 12 EHRA consensus documents, many of them in coordination with the Thrombosis Working Group of the ESC.
Member of the Guides Committee of the Spanish Society of Cardiology. Director of the Scientific Committee of the RECALCAR Project. Coordinator of the SEC-Excellent Project in Atrial Fibrillation of the Spanish Society of Cardiology.
Manuel Mayr qualified in Medicine from the University of Innsbruck (Austria) in 1999. He then moved to London to undertake a PhD. Upon completion of his PhD, he achieved promotion to Professor in 2011. He recently been awarded a prestigious British Heart Foundation Personal Chair. His academic achievements have been recognised by the inaugural Michael Davies Early Career Award of the British Cardiovascular Society (2007), the inaugural Bernard and Joan Marshall Research Excellence Prize of the British Society for Cardiovascular Research (2010), and the Outstanding Achievement Award by the European Society of Cardiology Council for Basic Cardiovascular Science (2013).
Dr. Lluís Mont was graduated in Medicine and Surgery on July of 1981 by the School of Medicine of Universitat de Barcelona. He obtained his Cardiologist Certificate in 1988. From 1989 until 1990 was research fellow in Electrophysiology at the University of Limburg at Maastricht (Netherlands) with Pere Brugada, PhD and Hein J Wellens, PhD, as mentors where he met Josep Brugada. Back in Barcelona, he worked at the University Hospital Vall d’Hebron, and lately, in 1996, he joined the arrhythmia team at the Hospital Clinic, under the direction of Dr. Josep Brugada. Currently, Dr. Mont is the Head of the Arrhythmia Section and responsible of the Atrial Fibrillation Unit of the Hospital Clinic de Barcelona. He has been involved in several research projects and multicenter studies about Atrial Fibrillation and Resincrhonization Therapy.
Giuseppe Patti received his MD and completed his fellowship at the Catholic University of Rome. He is Professor at Campus Bio-Medico University of Rome, where he is clinical and interventional cardiologist. He is certified in the role of Full Professor in Cardiology. His research interests focus on antiplatelet therapies in patients with acute coronary syndrome, on pharmacological and interventional approaches to prevent atrial fibrillation-related thromboembolic events, and on lipid-lowering strategies in high-risk patients with coronary artery disease. He was co-Chair of the ARMYDA Study Group, performing clinical studies on interventional pharmacology in patients undergoing coronary revascularization. He has authored over 130 original articles in a variety of peer-reviewed journals and acts as Reviewer for various international journals, including The Lancet, Circulation, European Heart Journal and Journal of the American College of Cardiology. He is Fellow of the European Society of Cardiology and of the American College of Cardiology. He has been Chair of the Working Group on Thrombosis of the Italian Society of Cardiology and is member of the National Council of the "Working Group on Atherosclerosis, Thrombosis and Vascular Biology” of the Italian Federation of Cardiology. He is a member of the Editorial Board of the "American Journal of Cardiovascular Disease" and the "Journal of Cardiovascular Medicine".
Title: Full Professor
Institution: Retired on October 1st 2017
1971 M.D. degree University of Padova
1974 Hematology Residency University of Padova, Italy
1976 Internal Medicine Residency University of Padova
1979 Cardiology Residency University of Padova
1992 Ph.D. University of Amsterdam
1980 University Researcher University of Padova
2000 Associate Professor University of Padova
2006 Full Professor University of Padova
1995 Visiting Professor of the Harvard Medical School (Boston, USA)
2008 Member of the Council of the Mediterranean League against Thromboembolic Diseases
2009 Member of the American College of Chest Physicians for the delivery of international guidelines for the treatment of venous thromboembolic disorders
2012 Eugene Strandness Lecturer, Orlando (USA)
2015 Lecturer at the Imperial College of London
2017 Max Ratschov Lecturer, Stoccarda
Research and Professional Experiences
Epidemiology, diagnosis and management of venous thromboembolism. Of particular interest are studies addressing the association of cancer with venous thromboembolism. Professor Prandoni has published almost 500 papers in peer-review journals. The main achievements were:
- The demonstration of the value of real-time compression ultrasonography for the diagnosis of DVT (NEJM 1989)
- the confirmation of the risk for subsequent overt cancer in patients with idiopathic VTE (NEJM 1992)
- the demonstration that LMWHs are as effective and safe as UFH in the treatment of DVT (Lancet 1992)
- the demonstration that LMWHs allow the home treatment of DVT (NEJM 1996)
- the description of the natural history of DVT, outlining the particularly high risk of recurrent thromboembolism in cancer patients (Ann Intern Med 1996)
- the demonstration that both factor V Leiden and G20210A prothrombin variant are independent risk factors for recurrent VTE (NEJM 1997, Blood 2000).
- the demonstration that residual vein thrombosis is a predictive marker of recurrent thromboembolism (Ann Intern Med 2002)
- the demonstration that cancer patients with venous thrombosis have a high risk of recurrent thromboembolism while on anticoagulation (Blood 2003)
- the demonstration of an association between atherosclerosis and venous thrombosis (NEJM 2003)
- the demonstration that chronic pulmonary thromboembolic hypertension following an episode of pulmonary embolism is more frequent than commonly thought (NEJM 2004)
- the demonstration that tailoring the duration of anticoagulation according to the persistence of residual vein thrombi reduces the risk of recurrent Thromboembolism (Ann Intern Med 2009)
- the demonstration that fondaparinux is effective and safe for the treatment of superficial vein thrombosis in the legs (N Engl J Med 2010)
- the demonstration that low-dose aspirin is effective for prevention of recurrent venous thrombormbolism (N Engl J Med 2012)
- the demonstration that pulmonary embolism has an unexpectedly high prevalence in patients hospitalized for syncope /N Engl J Med 2016)
- the value of low-dose rivaroxaban for the long-term protection of patients with VTE (N Engl J Med 2017)
Klaus T. Preissner studied Chemistry/Biochemistry in Cologne (Germany) and there he received his PhD in 1978. After a postdoctoral fellow at the Department of Immunology at the Scripps Clinic and Research Foundation, La Jolla, CA (1980-1983), he became principal group leader at the “Clinical Research Unit for Blood Coagulation and Thrombosis” in Giessen (1983-1997). Since 1998 he is Professor for Biochemistry and Pathobiochemistry at the Depart. Biochemistry, Justus-Liebig-University, Medical School, in Giessen. Previous research concentrated on mechanisms of cell adhesion (vitronectin) and proteolysis in vascular biology; current scientific activities are concerned with danger molecules and innate immunity mechanisms in cardiovascular diseases and thrombosis, particularly related to self-extracellular nucleic acids and new therapeutic concepts using endonucleases as cardio-protective drugs. He served as editor-in-chief (2003-2010) for “Thrombosis and Haemostasis” and was chairman (2009-2014) of an international graduate program “PROMISE” (Protecting the heart against ischemia), between Barcelona (Spain) and Giessen. He is (co)author of more than 330 peer-reviewed publications.
Bianca Rocca, MD, PhD is Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy). Prof. Rocca trained as Postdoctoral Fellow at the Center for Experimental Therapeutics, University Pennsylvania of Philadelphia (USA) with Prof. Garret A. FitzGerald. Prof. Bianca Rocca is Chairperson of the Working Group on Thrombosis of the European Society of Cardiology, is member of the Board of the Clinical Pharmacology section of the Italian Society of Pharmacology, of the Board of the Italian Group of Atherosclerosis, Thrombosis and Vascular Biology and she is listed in the Top Italian Scientists. She is member of the Editorial Board of the European Heart Journal-Cardiovascular Pharmacology, Pharmacology Research & Perspectives and Diabetes and Vascular Disease Research. She has been member of different Task Forces for ESC documents including guideline and position papers. She has co-authored over 100 articles, with over 6200 citations in peer-reviewed journals, including top journals such as: Annals of Internal Medicine, Atherosclerosis Thrombosis Vascular Biology, Blood, Circulation, Clinical Pharmacology and Therapeutics, European Heart Journal, Diabetes, Journal of the American College of Cardiology, Journal of Clinical Investigation, Nature Clinical Practice in Cardiovascular Medicine, Nature Medicine, Science, Proceedings of the National Academy of Science (USA). Her H-index is 40. Main scientific topics of interest are antiplatelet drugs, eicosanoids, primary haemostasis, platelets, non-steroidal anti-inflammatory drugs, anti-thrombotic prophylaxis of cardiovascular diseases.
Andrea Rubboli is Senior Interventional cardiologist at the Division of Cardiology, Ospedale Maggiore, Bologna, Italy. After earning cum laude both his MD degree and specialization in Cardiology at the University of Bologna Medical School, Italy, he completed subsequent training at Loyola University of Chicago, IL, USA and University of Linköping, Sweden.
Andrea Rubboli has long been interested in the diagnosis and treatment of thrombotic and thromboembolic diseases, both at the arterial and venous site. He carried out clinical studies on the diagnosis and treatment of acute pulmonary embolism, and served as Chairman of the Working Group on Diseases of the Pulmonary Circulation of the Italian Association of Hospital Cardiologists (ANMCO). He has pioneered the field of antithrombotic treatment of patients with indication for oral anticoagulation undergoing coronary stent implantation. On this issue, a substantial scientific contribution (also through national and international collaborations) has been produced, leading to the acquisition of international reputation, constant invitation as faculty member to the most important congresses, and involvement in the development of guidelines/international consensus documents. Andrea Rubboli has authored/co-authored 125 papers in peer-reviewed journals and has edited/co-edited two books on percutaneous coronary intervention in patients on oral anticoagulation. He is currently Secretary of the Working Group on Thrombosis of the European Society of Cardiology and President of the Italian Study Group on Atherosclerosis, Thrombosis and Vascular Biology (ATVB).
Manel Sabaté, MD, PhD; is Chief of the Interventional Cardiology Department at the Clinic University Hospital in Barcelona and Associate Professor of the Central University of Barcelona. From a professional point of view, Manel Sabaté’s experience includes diagnosis and treatment of ischemic heart disease and other cardiac disorders and he is specifically trained at cardiac catheterization and percutaneous coronary intervention and treatment of congenital and acquired structural heart disease including transcatheter aortic valve implantation and mitraclip implantation. From the research point of view, Manel Sabaté is author of more than 300 papers (h index 40), >20 book chapters and is the editor of 4 books. He is member of the editorial Board of several journals in the specialty and has been the recipient (as a Principal Investigator or Collaborator) in several competitive grants. It is also evaluating grants and projects from various agencies and he has received numerous awards for research work.
Doctor of philosophy, Faculty of Medicine at University of Oslo 1997
Professor of Cardiovascular Translational Science, Faculty of Medicine, University of Oslo 2008
Topics: Atherosclerosis, Coronary Artery Disease, Diabetes, Clinical translational studies, Haemostasis, Endothelial function, Inflammation
Position 1997-2008: Senior Scientist, Department of Cardiology, Oslo University Hospital Ullevaal
Position 2008- dd: Professor and Head of Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital Ullevaal and Institute of Clinical Medicine, University of Oslo, Norway
Supervisor of ∼ 40 PhD-student for their doctoral degree
260 original articles; ~ 360 congress abstracts; H-index 37
· Teaching medical students
· Adjudication Committees of ∼35 doctorial theses/professorships (Universities in Norway, Denmark and Sweden)
· Evaluation committees of Research Applications for funding
· Board member Institute of Clinical Medicine, Faculty of Medicine, University of Oslo
· Nucleus member of Biobank Development, Oslo University Hospital from 2001 to date
· Nucleus member of Working Group Thrombosis of the European Society of Cardiology 2012-16
Dirk Sibbing, MD, FESC, MHBA is Professor of Cardiology at the Ludwig-Maximilians University (LMU) in Munich. Prof. Sibbing trained and worked as fellow at the Deutsches Herzzentrum München from 2004-2012 under Prof. Albert Schömig and Prof. Adnan Kastrati. Since 2012 he works in his current position as senior doctor and interventional cardiologist at the department of cardiology at LMU Munich, where he also leads the study group on drugs in cardiovascular disease. Prof. Sibbing is listed among the 50 most frequently cited cardiovascular researchers in the German speaking area and has (co)-authored >120 articles with over 6000 citations in peer-reviewed journals, including: The Lancet, JACC, Circulation, European Heart Journal and Thrombosis & Haemostasis. His H-index is 32 and his main scientific interests are: coronary interventions, antiplatelet drugs, platelet function monitoring and genetics of cardiovascular disorders.
Dr. Siegbahn finished her MD at Uppsala University in 1974, and then had clinical residencies and fellowships in internal medicine, hematology and clinical chemistry.
She did her PhD in 1985, and founded the Coagulation Unit at the University Hospital in 1987. She became professor of Clinical Coagulation Science in 2000.
Dr. Siegbahn has had a large number of academic leadership positions for the past 30 years, amongst other things Member of the Board at Uppsala University, as well as the Swedish Reseach Council, Medicine. She has received a large number of prestigious awards, grants and has published more than 240 articles. Her research focus has been on clinical and translational studies of coagulation and thrombosis, where she is an internationally recognized leader.
In addition to this major contribution to the CVD literature, she has also played an important role in the increased use of protein biomarker discovery in clinical research in the Nordic region. She established the Uppsala Clinical Research Centre Laboratory in 2007, and then Clinical Biomarkers Facility at Science for Life Laboratory, Uppsala, Sweden in 2012.
Jolanta Siller-Matula, MD PhD, is Assoc. Professor at the Department of Cardiology at the Medical University of Vienna. As a PhD student, she carried out research on thrombin effects in vivo and in vitro at the Department of Clinical Pharmacology (Supervisor: Prof. Bernd Jilma). Thereafter, she expanded her research to fields of arterial thrombosis and personalized antiplatelet therapy (Department of Cardiology at the Medical University of Vienna), where she also leads the study group on Antithrombotic Treatment in Cardiovascular Indications. She is a (co-) author of > 80 peer-review articles with more than 4000 citations (h-index 32). Her publications have added to a debate in the cardiology community surrounding the efficacy and safety of conventional antiplatelet treatment and response variability to platelet inhibitors. She described the link between high platelet reactivity to clopidogrel and ischemic risk, the correlation between clinical factors and platelet reactivity, the effect of genetic polymorphisms and drug-drug interactions on the pharmacodynamics of antiplatelet drugs and clinical outcomes in patients with cardiovascular disease, and characterized von Willebrand Factor aptamers ARC15105 and ARC1779.
Education and Academic Career
1983 - 1987 Secondary school, Traun, Austria
1987 - 1992 Technical college for electronics, Leonding, Austria
1993 - 2000 Medical studies, University of Vienna
February 2011 University teaching thesis
October 2012 - Associate Professor, Internal Medicine
2000 - 2003 Research fellowship, University of Vienna,
Department of Internal Medicine II
2003 – 2006 and Residency, Medical University of Vienna,
2008 – 2011 Department of Internal Medicine II
2006 – 2008 Research fellowship, The Zena and Michael A. Wiener
Cardiovascular Institute, Mount Sinai School of Medicine,
New York, NY
2011 - 2014 Fellowship for cardiology and intensive care medicine
Medical University of Vienna, Department of Internal Medicine II
February 2014 - Deputy head of the cardiac critical care unit
Main Fields of Innate immune system
Research Inflammation and thrombosis in atherosclerosis
Monocytes and macrophages in inflammatory diseases
Biomarkers in cardiology and critical care medicine
Publications More than 70 Publications in medical journals with peer review
Impact factor > 300, h-index 24
European Heart Journal
Thrombosis and Haemostasis
Memberships Austrian Society of Cardiology since 2004
in Medical Societies Vice chairman of the working group “Intensive care medicine”
European Society of Cardiology since 2004
Member of the WG nucleus “Thrombosis”
American Heart Association since 2008
Austrian Society of Internal Medicine since 2012
European Atherosclerosis Society since 2013
Austrian Atherosclerosis Society since 2014
Academic Awards ISFP Special Achievement Award 2004
Award of the Austrian Society of Cardiology 2004 – Basic
Award of the Austrian Society of Cardiology 2005 – Clinical
Researcher of the month Dezember 2011, Medical University of
Award of the Austrian Society of Cardiology 2012 – Basic
Carl. S. Apstein Award 2012
Robert F. Storey
Robert F. Storey
Professor Robert Storey is Professor of Cardiology at the University of Sheffield, Sheffield, UK, where he has headed a thrombosis research group since 2002 and is director of the Cardiovascular Research Unit. In addition, Prof. Storey is Academic Director and honorary Consultant Cardiologist for the Cardiology and Cardiothoracic Surgery Directorate, Sheffield Teaching Hospitals NHS Foundation Trust. He has a special interest in the management of ischaemic heart disease, including acute coronary syndromes and coronary intervention.
He served as a member of the executive committees for the DISPERSE2, PLATO and PEGASUS-TIMI 54 studies, leading the platelet function substudies for these trials, and of the steering committees for the TRA-CER, EPICOR and ATLANTIC studies. He is currently a member of the steering committees for the COMPLETE, RAPID CTCA, SENIOR RITA, AUGUSTUS and CLEAR SYNERGY studies. He was Chair of the Working Group on Thrombosis of the European Society of Cardiology (ESC) from 2012-2014 and has been a Task Force member for several ESC guidelines on non-ST-elevation acute coronary syndromes (2011 and 2015) and dyslipidaemias (2011).
Hugo Ten Cate
Hugo Ten Cate
Graduated in medicine at the University of Amsterdam in 1987. The same year he completed his PhD thesis on “Clinical and experimental studies with a low molecular weight heparinoid”. He went for postdoctoral training to Beth Israel Hospital and Harvard Medical School Boston to expand studies on mechanisms of inflammation associated coagulation activity from 1988-1990. He trained in Internal medicine at Slotervaart hospital and Academic Medical Center Amsterdam (completed 1996). Clinical Established investigatorship from the Dutch Heart Foundation 1996-2002. Fellow, Gutenberg Research College, Gutenberg University, Mainz 2012-2016. Adjunct-professor, Center for Thrombosis and Haemostasis, Gutenberg University, Mainz, Germany 2017-.
Other relevant experience and professional memberships: Chairman of the board, Dutch Federation of Anticoagulation clinics (FNT; 2011-), Fellow American Heart Foundation, Member American Society of Hematology, Member International Society of Thrombosis and Haemostasis, Professional Member European Society of Cardiology. Editorial boards: Journal of Thrombosis and Haemostasis, Arteriosclerosis, Thrombosis and Vascular Biology, Science Open; Academic Editor, PlosOne; Section editor Thrombosis and Haemostasis; Editor-in-chief (jointly with dr. Yukio Ozaki) Thrombosis Journal.
His research focus is on mechanisms of hypercoagulability in complex cardiovascular disease, including atherothrombosis, atrial fibrillation and ischemic stroke. He is PI in the CVON programs RACE-5 and CONTRAST.
Arina Ten Cate
Arina Ten Cate
Dr. Arina ten Cate-Hoek is an experienced clinician in the practice of thrombosis and haemostasis (Thrombosis clinic, Maastricht University Medical Centre (MUMC+). She holds an MD, a PhD in medicine, and a Master degree in clinical epidemiology. She is the medical director of the Maastricht Anticoagulation Clinic and the Medical coordinator for the Thrombosis Expertise Center Maastricht. She chairs several committees among which the committee for standardization of medical treatment with vitamin K antagonist (Federation of Dutch Thrombosis Services), the international guideline committee on compression therapy (European College of Phlebology) etc. She is a lecturer at Maastricht University Medical School and is actively involved in clinical research. The focus of her research is on the diagnosis prevention and treatment of venous thrombosis and its long-term effects.
Gianna Maria Toffolo graduated summa cum laude in Electronic Engineering at the University of Padova in 1978. From 2000 she is a Full Professor of Bioengineering at the University of Padova. She is a member of the PhD School in Information Engineering and from 2009 to 2017 she chaired the graduate Program in Biomedical Engineering.
Her research activity, carried out in collaboration with Italian and foreign investigators, mainly regards modeling of biological and physiological systems, at whole body, organ, molecular and sub molecular levels. It includes methodological aspects as well as specific applications in biology, physiology and medicine. Particular importance is given to areas including glucose metabolism, insulin secretion and signalling, amino acid kinetics and protein turnover, gene and protein regulatory networks, quantitative analysis of electrophysiological signals.
She is author/coauthor of a book and more than 150 full papers on international peer reviewed journals (ISI Web of Science: H Index=40; total number of citations=5040; selfcitations excluded=4662; Google Scholar: H Index=54; total number of citations 11004).
She coordinated as p.i. three MIUR research projects (PRIN2000, PRIN2003, PRIN2005), an Excellence Project funded by CARIPARO Foundation (2008-2011) and participates as co-investigator in several NIH, JDFR and EU projects.
She serves as consulting editor for Diabetes and as external referees for many journals.
Current positions Scientific Director of the Centro Cardiologico Monzino, Milano
Full Professor of Pharmacology
President of the IRCCS Cardiology Network
Education and training
Degree in Pharmacological Sciences, University of Pavia
Research Fellow at Centro Enrica Grossi Paoletti, University of Milano.
Experiences abroad Research activities in the Division of Hematology / Oncology, Cornell Medical Center, New York Hospital, under the supervision of Prof. Ralph Nachman (1980-1981)
From 1990 to 2015, Prof. Tremoli has been Head of the Laboratory of Pharmacology of Thrombosis and Atherosclerosis, Department of Pharmacological Sciences, University of Milano
From 2003 to 2009, Director of the Department of Pharmacological Sciences, University of Milano.
Since 2001 she has been Head of the Laboratory of Biochemistry and Molecular Biology of Atherothrombosis, Centro Cardiologico Monzino
Since July 2011, Scientific Director of the Centro Cardiologico Monzino
Research interests Prof. Tremoli’s research interests are focused on the study of cardiovascular diseases with particular attention to the identification and development of new markers of atherothrombosis. The research is focused on cellular and molecular studies in experimental animals and in humans, particularly in patients with cardiovascular diseases.
Below, the main topics of research:
• molecular and cellular biology of atherosclerosis and thrombosis with particular attention to the regulation of inflammatory and thrombotic system proteins in vascular cells, in blood and in tissues such as heart pieces, valves, vascular fragments isolated from humans and experimental animals, including genetically modified mice.
• pharmacological control of thrombus formation: studies on blood cells and vascular wall, with particular attention to platelets and coagulation/fibrinolysis factors. Monitoring the effectiveness of
old and new therapies and identification of coagulation and platelet activation markers in patients with cardiovascular diseases.
• studies of cerebral and myocardial ischemia in animals, including genetically modified mice, using MRI imaging and other innovative imaging methods.
• morphology and function of the vascular wall: imaging studies using ultrasounds in populations with risk factors for cardiovascular disease. Identification of markers of disease and their therapeutic monitoring.
• studies of genetics, genomics, proteomics and metabolomics in selected patients with risk factors for cardiovascular disease. Awards Award of the International Society of Atherosclerosis for the “ XXth anniversary of the description of carotid intima-media thickness as diagnostic tool", Rome, June 22nd, 2006
Award of the European Society for Non-Invasive and Preventive Cardiology for the "outstanding contribution to non-invasive cardiovascular imaging and preventive cardiology", Brescia, May 2009
436 peer reviewed publications
Number of citations (Scopus) = 17.816
H index (Scopus) = 63
Participation in projects Prof. Tremoli coordinated 6 projects funded by the European Commission, 6 research projects funded by the Ministry of Health, 1 project funded by the National Institute of Health, 1 project funded by Regione Lombardia and 1 FIRB project funded by the MIUR.
Prof. Tremoli was also Head of Research Unit in 4 Scientific Research Programs of Relevant National Interest (PRIN) funded by MIUR.
José Tuñón, MD, PhD, FESC, FACC, is Associate Chief of the Department of Cardiology in Fundación Jiménez Díaz and Associate Professor of the Autónoma University, both in Madrid, where he serves also as Academic Secretary of the Department of Medicine.
He is a clinical cardiologist involved in research in the fields of atherosclerosis, specifically in the areas of inflammation, biomarkers, proteomics, mineral metabolism, and lipid-lowering therapy. At present, he is serving as a Nucleus Member of the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology and Vice-Secretary of the Castilian Society of Cardiology.
He has obtained 25 competitive grants as principal investigator, and is the author of more than 150 papers and book chapters in national and international journals, including Circulation, JACC, European Heart Journal, Stroke, Cardiovascular Research, Atherosclerosis, American Journal of Cardiology, Journal of Proteome Research, and Proteomics, among others. He has done more than 180 lectures at National and International Congresses.
Anne Tybjærg-Hansen MD DMSc, Professor, Chief Physician.
Chief Physician at the Department of Clinical Biochemistry, Section for Molecular Genetics, at Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark (from Nov. 1999).
Professor of Clinical Biochemistry with Focus on Translational Molecular Cardiology at the University of Copenhagen, Copenhagen, Denmark (from Dec. 2009).
Graduated as a medical doctor from the University of Copenhagen in 1981. Scientific education included 1 year at the University of Copenhagen and the Lipid Clinic at Righospitalet , 3 years at Hagedorn Research Laboratory, Gentofte, Denmark; and 3 years (87-89) at British Heart Foundation’s Molecular Biology Research Group, London, UK.
Member of the steering committees of the Copenhagen City Heart Study and the Copenhagen General Population Study. Current chairman European Lipoprotein Club.
Recipient of the European Atherosclerosis Society’s Anitschkow Prize for 2018.
Highly Cited Researcher, ranking in the top 1% by citations and field and publication year in the World in Web of Science 2017.
Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands
Professor Freek Verheugt is Emeritus Professor of Cardiology at the Heart-Lung Centre of the University Medical Centre of Nijmegen, The Netherlands, and was Chairman of the Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) in Amsterdam, The Netherlands.
Prof. Verheugt graduated from the University of Amsterdam in 1974 and wrote a thesis on platelet and granulocyte antigens and antibodies. He trained in cardiology at the Thoraxcenter of the Erasmus Medical Centre, University in Rotterdam. He has been a Professor at the University of Colorado Health Sciences Center in Denver, CO, USA, and at the Free University in Amsterdam. He was President of the Netherlands Society of Cardiology between 1999 and 2001. Prof. Verheugt’s main fields of scientific interest are pharmacological and interventional treatments of acute coronary syndromes and atrial fibrillation.
Prof. Verheugt has published over 500 papers in peer-reviewed international journals including The New England Journal of Medicine, The Lancet, Circulation, Journal of the American College of Cardiology and European Heart Journal, of which he is an Associate Editorial Board Member for clinical reviews. He has over 26,000 citations, an H-index of 69 and is also an editorial advisor of The Lancet, The New England Journal of Medicine and Circulation.
Henri H. Versteeg is a full professor at the Department of Internal Medicine at the Leiden University Medical Center and the chair of the division of Thrombosis and Hemostasis. He is also an editor in chief for the journal Thrombosis Research and a regular reviewer for various journals. Dr Versteeg obtained his PhD from the University of Amsterdam and received training as a postdoctoral fellow at the Scripps Research Institute, La Jolla, USA and the LUMC, Leiden, Netherlands. His work focuses on the impact of coagulation and coagulation factors on cancer progression, and recently, he started investigating the molecular and genetic basis of cancer-associated thrombosis. His work is published in journals such as Nature Medicine, PNAS, Journal of Thrombosis and Haemostasis, Circulation Research and Blood and he has been awarded the NovoNordisk Haemostasis Award and the Parijs award for best translational research, as well as a number of prestigious fellowships. Dr Versteeg is currently funded by the Netherlands Organisation for Scientific Research, the Dutch Cancer Society and Wordlwide Cancer research.
Dr. Gemma Vilahur is a Senior I3P Researcher at the Cardiovascular Science Program (ICCC) Institut de Recerca, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau in Barcelona. Her translational research activities focus on ischemic heart disease, from atherothrombosis to cardioprotection. She has published 111 articles in peer reviewed journals in the cardiovascular field including original manuscripts, consensus and position papers, and reviews and has contributed to 27 book chapters (H-index: 26; total citations: 2248). She is part of the Editorial Board of prestigious Scientific Journals in the Cardiovascular Field (Cardiovascular Research, Vascular Phamacology, Cardiovascular Drugs and Therapy) and the author of three patents related with cardioprotection.Her previous appointments include: Post-doctoral fellowship from the Spanish Ministry of Economy and Competitiveness at the Cardiovascular Biology Research Laboratory, Zena and Michael A.Wiener Cardiovascular Institute at the Mount Sinai School Medicine, New York, USA (2004-2006); Juan de la Cierva Researcher at the Spanish Ministry of Science and Education, (2006-2009); Ramon y Cajal Researcher from the Science and Innovation Ministry of Spain (MICINN; 2009-2014). Awards and Honors: she has been awarded by the European Society of Cardiology – ESC [Berlin 2002, Vienna 2003, Vienna 2007, Munich 2008 (young investigation award), London 2015], she has received the First Prize in the National Congress of Cardiology (Madrid 2007; Seville 2012), First and second Prize in the National Congress of Atherosclerosis (Pamplona 2009 and Zaragoza 2013, respectively), the Northwestern Cardiovascular Young Investigator's Forum and the Arteriosclerosis, Thrombosis, and Vascular Biology Merit Award of the American Heart Association (AHA; Chicago 2006) and has been awarded by L’Oreal-UNESCO foundation - for Women in Science (2012).Positions of trust: she was elected Nucleus member of the Working Group of Thrombosis of the European Society of Cardiology (ESC; 2014-2018) and further became the treasurer of this Working Group (2016-2018). She is the founder of the Scientists of Tomorrow (2013-2016) working closely and under the umbrella of the Council of Basic Cardiovascular Science – European Society Cardiology.
Charalambos Vlachopoulos is an Associate Professor of Cardiology at the 1st Department of Cardiology, Hippokration Hospital, University of Athens Medical School with clinical interests in hypertension, lipids and interventional cardiology.
Professor Vlachopoulos is immediate past-President of the ARTERY Society and past-Chairman of the European Society of Cardiology Working Group "Peripheral Circulation".
He researches arterial biomarkers with special interests on the predictive role of arterial stiffness and central pressures for cardiovascular events, on the effect of lifestyle and inflammation on arterial function, and on the relation between cardiovascular disease and sexual dysfunction. His research interests extend to pathophysiology of hypertension, lipids and the identification vulnerable plaque.
Professor Vlachopoulos has published more than 250 peer-review articles and has been cited in over 33,000 referenced publications in international peer-reviewed journals and medical textbooks of leading international publishers. His H-index is 61. He is a co-author of the 2016 European Society of Cardiology/European Atherosclerosis Society Guidelines for the Management of Dyslipidaemias and of the 2017 European Society of Cardiology Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases. Together with Wilmer Nichols and Michael O'Rourke he has authored the 6th Edition of "McDonald's Blood Flow in Arteries". He has lectured extensively in international conferences.
He is a member of the Board of Hypertension, Artery Research, and Hellenic Journal of Cardiology and a Reviewer for numerous Medical Journals.
Lars Wallentin is senior professor of Cardiology and founder and first leader of the Uppsala Clinical Research Centre (UCR) at Uppsala University Hospital, Uppsala, Sweden. Prof Wallentin has been President of the Swedish Cardiac Society and the Swedish Heart Association and also founded and been the first chairman of the Swedish Cardiovascular Registries. The research group of professor Wallentin has developed many new concepts concerning pathogenesis, diagnosis, risk stratification, and antithrombotic and interventional treatments in acute coronary artery disease and stroke prevention in atrial fibrillation. Prof Wallentin has published more than 650 papers in peer-reviewed international journals and has received several prestigious awards.
Health Care Management, University of Economics, Vienna 2017-18
Chair, (o. Univ. Prof.) of Cardiology, Sigmund Freud Private University, Vienna, since Aug 2016
Fellow of the European Society of Cardiology (FESC) since December 2015
Senior Lecturer, (Priv.-Doz.) for Vascular Biology, Medical University of Vienna, since Jun 2011
Thesis: Inflammation, angiogenesis and matrix stability in cardio- and cerebrovascular disease.
Dr. phil. (PhD), Faculty of Medicine at the University of Oslo, Norway, Sep 2012
Thesis: Inflammation, Adipose tissue and Atherosclerosis.
Dr. med. (MD), Faculty of Medicine at the University of Vienna, Austria, Nov 2003
Thesis: Role and regulation of the Plasminogen system in the human heart.
Foreign exchange student with AFS in Guanare, Venezuela, Jul 1993 – Jun 1994.
Appointment as Deputy Head of the 3rd Medical Dept, Wilhelminenhospital, in December 2015
Appointment as Consultant Cardiologist, Wilhelminenhospital, in October 2015
Member of the Interventional Cardiology Team at Wilhelminenhospital, Vienna, since May 2014
Head of Hypertension Clinic and Cardiology Ward at Wilhelminenhospital, Vienna, since Jan 2013
Accreditation as Specialist in Cardiology by the Austrian Medical Council, Jun 2014
Accreditation as Specialist in Internal Medicine by the Austrian Medical Council, Jun 2012
Specialist Training in Internal Medicine, Cardiology and Intensive Care Medicine at Oslo University Hospital, Norway; Alfred Hospital, Monash University, Melbourne, Australia; Wilhelminenhospital and Otto Wagner Hospital, Vienna, Austria; Aug 2004 – May 2014
Senior Research Officer, Australian Centre for Blood Diseases, Monash University Melbourne, Australia; 2004 - 2006
Research Fellow, Department of Internal Medicine II, Division of Cardiology, University of Vienna, Austria; 1999 – 2004; Aug 2006 – Dec 2007; from 2012
AWARDS and SCHOLARSHIPS:
2014 Werner Klein Award of the Austrian Hypertension League
2007 Research Award of the Vienna Medical Association
2005 Young Investigator Award of the ISTH
2005 Austrian Cardiologists’ Award - Category Basic Research
2004 Special Achievement Award of the ISFP
2004-06 Erwin-Schrödinger Fellowship of the Austrian Science Fund (FWF)
2000 - 2003 Several Scholarships of the University of Vienna and Austrian Cardiology Society
SELECTED ORAL PRESENTATIONS ON INVITATION:
Optimal Duration of Dual Antiplatelet Therapy. Presented at CSI 2017, Calcutta, India.
Richard Wagner and Coronary Heart Disease. Presented at Sound and Science, Konzerthaus, Vienna, Austria. 2015.
Adipose Tissue and Atherothrombosis. Presented at FCVB 2014, Barcelona, Spain.
Hypertension Control – How to bring stakeholders together. Presented at ESC 2015, London, UK.
Renal Denervation – A novel concept for hypertension and other indications. Presented at the Vienna Vascular Days 2013, Vienna, Austria
Metabolic Syndrome and and Atherosclerosis, ESC 2013, Amsterdam, The Netherlands.
Crosstalk between the MMP/TIMP system and the plasminogen system, Nordic Coagulation Meeting 2009, Oslo, Norway.
Lectures and Seminars at the Sigmund Freud Private University and Medical University Vienna and University of Oslo, including ECG interpretation, Doctor-Patient Communication, Physical Examination, continously since 2006
Supervisor for Dr. med. Sophie Schumacher from 2007, Thesis: Infectious Burden and In-Stent Restenosis, defended January 2010
Supervisor for Dr. med. Anna Wonnerth from 2006, Thesis: G148A – polymorphism of the glycoprotein 130 is associated with coronary artery disease, defended January 2009
Current supervisor of PhD Students Vibeke Ritschel and Ragnhild Helseth at University of Oslo and Miklos Rohla, Tijana Andric and Maximilian Tscharre at the Medical University of Vienna.
Many years of experience in acute cardiac care, cardiac arrest team, medical emergency team, ICU/CCU, echocardiography, electrocardiography, pacemaker/ICD outpatients and heart failure. Excellence in conservative and invasive hypertension management (RDN) and coronary angiography and intervention (PCI).
STATEMENT ON CLINICAL RESEARCH EXPERIENCE AND FOCUS:
Main research focus: Antithrombotic therapy in ACS and hypertension management.
Identifying interactions between hypertension, obesity, inflammation and atherothrombosis, by applying a translational approach, using registries, randomised clinical trials, in vivo and in vitro models.
Initiator of the “Saxagliptin in atherosclerosis” SAXATH trial, the ATTAIN registry, the EAT ME registry, the LOW BP VIENNA trial, AWARENESS and CONTROL of HYPERTENSION in AUSTRIA.
OTHER PROFESSIONAL ACTIVITIES:
Secretary of the Austrian Society of Hypertension since November 2016
Congress President of the Austrian Society of Hypertension Meeting 2016 in Vienna
Board Member of the Austrian Society of Hypertension since April 2015
Congress Secretary for the GTH Meeting 2014 in Vienna
Congress President for the Renal Denervation Meeting 2013 in Vienna
Congress Secretary for the Eurothrombosis Summit 2012 in Vienna
Member of the Nucleus of the Working Group Thrombosis of the ESC 2012 - 2016
Member of the Nucleus of the Working Group ATVB of the Austrian Cardiac Society since 2012
Member of the Editorial Board of the European Journal of Cardiovascular Medicine, since 2011
Doctor of trust to the Embassy of the Republic of Austria in Norway, 2009-2012
Reviewer for the JTH, Thromb Haemost, Int J Cardiol, Clin Res Cardiol, etc.
Member of the Research Board of the Vienna Medical Association 2007-2009
Member of the International Society for Fibrinolysis and Proteolysis since 2004
Member of the ESC Working Group “Thrombosis” since 2007
SOCIAL ACTIVITIES AND COMMITMENTS:
Founding Member of the “Youth Against Racism in Europe” Movement in 1992
Team Captain of the Football Club Torpedo Donaustrom Vienna 1999-2003
Native language: German
Fluently: English, Norwegian, Swedish, Danish, Spanish
Basic knowledge: Portuguese, French
Johann Wojta, PhD, is Associate Professor of Medical Physiology at the Medical University of Vienna, Head of Research at the Division of Cardiology and Head of Core Facilities. He obtained his PhD in Zoology in 1986 at the University of Vienna and since then has done research in the area of cardiovascular biology with a focus on atherosclerosis. He has published more than 290 papers in peer-reviewed journals and he has a Hirsh-index of 56 according to google scholar. He has been Nucleus Member of the ESC Working Group on Thrombosis from 2010 to 2014, an ex-officio Nucleus Member from 2015 to 2016 and is currently an affiliated Nucleus Member from 2017 to 2018.